Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B

Table 1 Demographic data and clinical features of the study group n (%)

Characteristic	Total	YMDD variants	Without YMDD variants	P value
	(n = 1268)	(n = 288)	(n = 980)
Age (yr)	42.12 ± 13.24	42.42 ± 14.25	43 ± 12.15	0.812
Sex
Male	923 (72.79)	205 (71.18)	718 (73.26)	0.485
Female	345 (27.21)	83 (28.82)	262 (26.73)	0.485
Alcohol use
Yes	143 (11.3)	36 (12.5)	107 (10.9)	0.456
No	1125 (88.7)	252 (87.5)	873 (89.1)
Family history1
Yes	613 (48.3)	118 (41)	495 (50.5)	0.004
No	655 (51.7)	170 (59)	485 (49.5)
Aspartate aminotransferase (IU/L)	53 ± 25	56 ± 24	54 ± 23	0.963
Alanine aminotransferase (IU/L)	67 ± 26	63 ± 33	69 ± 31	0.012
Alkaline phosphatase (IU/L)	102 ± 45	106 ± 46	112 ± 54	0.064
Gamma-glutamyl transpeptidase (IU/L)	26 ± 4	25 ± 3	26 ± 3	0.852
HBV genotype
A	5 (0.4)	2 (0.7)	3 (0.3)	0.320
B	284 (22.4)	72 (25)	212 (21.6)
C	971 (76.6)	211 (73.3)	760 (77.6)
Others	8 (0.6)	3 (1.0)	5 (0.5)
HBeAg status
Positive	543 (42.8)	106 (36.8)	437 (44.6)	0.019
Negative	725 (57.2)	182 (63.2)	543 (55.4)
HBV DNA (LGE)	6.67 ± 2.47	7.27 ± 3.16	6.37 ± 2.64	0.024

Data are expressed as mean ± SD or as n (%).

¹Family history of positive hepatitis B surface antigen, including third-degree relatives. YMDD variants (n = 288, 22.71%), without YMDD variants (n = 980, 77.28%). LGE: Log10 genome equivalents; YMDD: Tyrosine-methionine-aspartic acid-aspartic acid; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen.